This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eisenberg, P. R. Articles by Bovill, E. G. Search for Related Content PubMed PubMed Citation Articles by Eisenberg, P. R. Articles by Bovill, E. G.

Circulation, Vol 82, 1159-1168, Copyright © 1990 by American Heart Association

ARTICLES

Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis

PR Eisenberg, AS Jaffe, DC Stump, D Collen and EG Bovill
Cardiovascular Division, Washington University School of Medicine, St. Louis, Missouri 63110.

Concentrations of cross-linked fibrin degradation products (XL-FDPs) in plasma, measured by enzyme-linked immunosorbent assays (ELISAs) based on monoclonal antibodies (MAbs) raised against fragment D-dimer of cross-linked fibrin, increase when patients are given fibrinolytic agents. Whether XL-FDPs derive from circulating cross-linked fibrin polymers in plasma, compared with clot-associated fibrin, has been questioned because increases in XL-FDP are measured by some assays after fibrinolysis in vitro in the absence of clot. We characterized the source of XL-FDP immunoreactivity in plasma of patients with acute myocardial infarction and ischemic heart disease and the response to plasminogen activation in vitro induced by pharmacological concentrations of tissue-type plasminogen activator (t-PA) and streptokinase. XL-FDPs were measured with two different ELISA. One, "pan-specific tag ELISA," was based on a capture MAb specific for XL- FDP and a tag MAb that recognizes an epitope exposed in the fragment D region of both fibrin and fibrinogen, whereas the other, "fibrin- specific tag ELISA," was based on a capture and tag MAbs both specific for fibrin. After plasminogen activation was induced in vitro in plasma from patients with myocardial infarction, increased concentrations of XL-FDP were measured by the pan-specific tag ELISA; however, concentrations measured with the fibrin-specific tag ELISA were not increased. To determine the mechanism for this discrepancy, plasma was subjected to immunoadsorption with a MAb specific for fragment D-dimer before and after in vitro activation of the fibrinolytic system and immunoblotting with a fragment D-dimer-specific MAb and with the pan- specific MAb. Increased concentrations of fragment D-dimer, as well as fibrinogen fragment D at high concentrations, were recognized by the specific MAb. Non-cross-linked fragments were also shown by immunoblotting with the pan-specific MAb to coprecipitate with cross- linked fibrin fragments. This suggested the increased concentrations of XL-FDP measured by the pan-specific tag ELISA after in vitro activation of the fibrinolytic system were due to detection of non-cross-linked fibrinogen fragments. However, fibrin fragment D-dimer concentrations were found to increase in plasma of 15 patients given t-PA for acute myocardial infarction. We conclude fragment D-dimer in plasma of patients during thrombolysis does not originate from circulating soluble cross-linked fibrin but rather is a marker of solid-phase fibrin dissolution, which may be quantitated with assays based on capture and tag antibodies that do not detect fibrinogen or its degradation products.

This article has been cited by other articles:

				L. H. Edmunds Jr and R. W. Colman Thrombin During Cardiopulmonary Bypass Ann. Thorac. Surg., December 1, 2006; 82(6): 2315 - 2322. [Abstract] [Full Text] [PDF]

				A Wakai, A Gleeson, and D Winter Role of fibrin D-dimer testing in emergency medicine Emerg. Med. J., July 1, 2003; 20(4): 319 - 325. [Abstract] [Full Text] [PDF]

				L. V. Lee, G. A. Ewald, C. R. McKenzie, and P. R. Eisenberg The Relationship of Soluble Fibrin and Cross-linked Fibrin Degradation Products to the Clinical Course of Myocardial Infarction Arterioscler Thromb Vasc Biol, April 1, 1997; 17(4): 628 - 633. [Abstract] [Full Text]

				D. M. Becker, J. T. Philbrick, T. L. Bachhuber, and J. E. Humphries D-Dimer Testing and Acute Venous Thromboembolism: A Shortcut to Accurate Diagnosis? Arch Intern Med, May 13, 1996; 156(9): 939 - 946. [Abstract] [PDF]